Document Detail


RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer.
MedLine Citation:
PMID:  21076616     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
We recently demonstrated highly efficient antitumor immunity against dermal tumors of B16F10 murine melanoma with the use of dendritic cells (DCs) activated by replication-competent, as well as nontransmissible-type, recombinant Sendai viruses (rSeV), and proposed a new concept, "immunostimulatory virotherapy," for cancer immunotherapy. However, there has been little information on the efficacies of this method: 1) in more clinically relevant situations including metastatic diseases, 2) on other tumor types and other animal species, and 3) on the related molecular/cellular mechanisms. In this study, therefore, we investigated the efficacy of vaccinating DCs activated by fusion gene-deleted nontransmissible rSeV on a rat model of lung metastasis using a highly malignant subline of Dunning R-3327 prostate cancer, AT6.3. rSeV/dF-green fluorescent protein (GFP)-activated bone marrow-derived DCs (rSeV/dF-GFP-DC), consistent with results previously observed in murine DCs. Vaccination of rSeV/dF-GFP-DC was highly effective at preventing lung metastasis after intravenous loading of R-3327 tumor cells, compared with the effects observed with immature DCs or lipopolysaccharide-activated DCs. Interestingly, neither CTL activity nor DC trafficking showed any apparent difference among groups. Notably, rSeV/dF-DCs expressing a dominant-negative mutant of retinoic acid-inducible gene I (RIG-I) (rSeV/dF-RIGIC-DC), an RNA helicase that recognizes the rSeV genome for inducing type I interferons, largely lost the expression of proinflammatory cytokines without any impairment of antitumor activity. These results indicate the essential role of RIG-I-independent signaling on antimetastatic effect induced by rSeV-activated DCs and may provide important insights to DC-based immunotherapy for advanced malignancies.
Authors:
Tomonori Kato; Yasuji Ueda; Hiroaki Kinoh; Yasuo Yoneyama; Akinao Matsunaga; Atsushi Komaru; Yui Harada; Hiroyoshi Suzuki; Akira Komiya; Satoko Shibata; Mamoru Hasegawa; Hideki Hayashi; Tomohiko Ichikawa; Yoshikazu Yonemitsu
Related Documents :
19121816 - New insights into the roles of dendritic cells in intestinal immunity and tolerance.
19338746 - Adenosine primes resting stage dendritic cells before their activation.
20686116 - Pparγ modulated inflammatory response of human dendritic cell subsets to engulfed apop...
12924606 - Immunotherapy exploiting the versatility of dendritic cells.
20519446 - Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic...
20535576 - Cell sheet integrity and nanomechanical breakdown during programmed cell death.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neoplasia (New York, N.Y.)     Volume:  12     ISSN:  1476-5586     ISO Abbreviation:  Neoplasia     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100886622     Medline TA:  Neoplasia     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  906-14     Citation Subset:  IM    
Affiliation:
Department of Gene Therapy, Chiba University Graduate School of Medicine, Chiba, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Loss of STAT1 from mouse mammary epithelium results in an increased neu-induced tumor burden.
Next Document:  Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast gr...